{"id":"NCT00375505","sponsor":"Novartis Pharmaceuticals","briefTitle":"The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss","officialTitle":"Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2006-09-13","resultsPosted":"2015-09-07","lastUpdate":"2015-09-07"},"enrollment":70,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Zoledronic acid","otherNames":["ZOL446, zoledronic acid, Zometa"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Zometa","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment","primaryOutcome":{"measure":"Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24","timeFrame":"baseline, month 24","effectByArm":[{"arm":"Placebo","deltaMin":-0.075,"sd":0.041},{"arm":"Zometa","deltaMin":0.037,"sd":0.042}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":["38979716"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":36},"commonTop":["ARTHRALGIA","HOT FLUSH","MENOPAUSAL SYMPTOMS","LYMPHOEDEMA","BONE PAIN"]}}